GlassScriptPhysician profile
Michelle C Chambers
NPI 1538152954
$3,974.46
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $1,242 · 2021: $1,158 · 2022: $55.66.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.97 | 2019-2022 | |
| Genzyme Corporation | $332.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $316.70 | 2019-2021 | |
| Amgen INC. | $307.93 | 2019-2021 | |
| Lilly USA, LLC | $270.71 | 2019-2021 | |
| Galderma Laboratories, L.P. | $235.09 | 2019-2021 | |
| Pfizer INC. | $209.20 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $190.11 | 2019-2021 | |
| Celgene Corporation | $186.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $155.73 | 2019-2021 | |
| Journey Medical Corporation | $140.17 | 2019-2020 | |
| Leo Pharma INC. | $123.23 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $101.52 | 2020-2022 | |
| Janssen Biotech, INC. | $93.15 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $68.56 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $61.46 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $57.24 | 2019 | |
| Ucb, INC. | $52.57 | 2021 | |
| Merz North America, INC. | $37.28 | 2019-2020 | |
| Novum Pharma, LLC | $31.15 | 2019 | |
| Dermira, INC. | $26.41 | 2019-2021 | |
| Allergan, INC. | $24.26 | 2022 | |
| Sandoz INC. | $23.76 | 2020 | |
| Incyte Corporation | $15.62 | 2021 | |
| Epi Health, LLC | $15.61 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.23 | 2020 | |
| Almirall LLC | $13.18 | 2019 | |
| Mission Pharmacal Company | $11.17 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$7,206.22 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.